The new information brought by our work describing the role of NADPH oxidase activation during ADCC by PMN and its regulation by SIRPα might help to design new agents to enhance myeloid cell function in the treatment of cancer while limiting adverse effects on healthy cells. The gene discussed is FMO5; the disease is cancer.